Yung DPHIL - Prenetics Global Chief Officer
| PRE Stock | USD 4.42 0.30 6.36% |
Executive
Yung DPHIL is Chief Officer of Prenetics Global
| Age | 42 |
| Address | Unit 703-706, K11 Atelier King?s Road, Quarry Bay, Hong Kong |
| Phone | 852 2210 9588 |
| Web | https://www.prenetics.com |
Prenetics Global Management Efficiency
The company has Return on Asset of (0.1031) % which means that on every $100 spent on assets, it lost $0.1031. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2167) %, meaning that it generated no profit with money invested by stockholders. Prenetics Global's management efficiency ratios could be used to measure how well Prenetics Global manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.31. The current year's Return On Capital Employed is expected to grow to -0.23. At present, Prenetics Global's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 13.2 M, whereas Other Assets are projected to grow to (7.9 M).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Bernhard Spiess | Castle Biosciences | 64 | |
| Kristen RN | Castle Biosciences | 56 | |
| Jeffrey Krupp | Inotiv Inc | 53 | |
| Adrian Hardy | Inotiv Inc | 53 | |
| Hao Liu | Burning Rock Biotech | 50 | |
| Elizabeth Tallett | Qiagen NV | 71 | |
| Stephane Bancel | Qiagen NV | 47 | |
| Matthew MD | Castle Biosciences | N/A | |
| Jon Jacobsen | Aclaris Therapeutics | N/A | |
| Tobin Juvenal | Castle Biosciences | 64 | |
| Kevin Doman | Castle Biosciences | N/A | |
| Lizanne Muller | Inotiv Inc | N/A | |
| Alice Izzo | Castle Biosciences | N/A | |
| Xiaozhi Hu | Burning Rock Biotech | N/A | |
| Mark DeBlock | Biodesix | N/A | |
| Amy Rocklin | Neogen | 52 | |
| JeanPascal Viola | Qiagen NV | N/A | |
| Brennan Freeman | Inotiv Inc | 37 | |
| Sarah Demey | Neogen | N/A | |
| Antonio Santos | Qiagen NV | N/A | |
| Bill Waelke | Neogen | N/A | |
Management Performance
| Return On Equity | -0.22 | |||
| Return On Asset | -0.1 |
Prenetics Global Leadership Team
Elected by the shareholders, the Prenetics Global's board of directors comprises two types of representatives: Prenetics Global inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Prenetics. The board's role is to monitor Prenetics Global's management team and ensure that shareholders' interests are well served. Prenetics Global's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Prenetics Global's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Senthil MD, Chief Officer | ||
| Yvonne Wong, Chief Officer | ||
| Avrom Lasarow, Chief EMEA | ||
| Yung DPHIL, Chief Officer | ||
| Samantha Kwok, People President | ||
| Sheng Yeung, Chairperson CoFounder | ||
| Joel Neoh, Chief CircleDNA | ||
| Hoi Lo, Chief Officer | ||
| Walt Ling, Chief Genomics | ||
| Chi Tzang, CoFounder Officer | ||
| ShihChang MD, Chief Board |
Prenetics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Prenetics Global a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.22 | |||
| Return On Asset | -0.1 | |||
| Profit Margin | (2.20) % | |||
| Operating Margin | (1.79) % | |||
| Current Valuation | 4.27 M | |||
| Shares Outstanding | 10.64 M | |||
| Shares Owned By Insiders | 21.40 % | |||
| Shares Owned By Institutions | 13.18 % | |||
| Number Of Shares Shorted | 38.69 K | |||
| Price To Earning | 144.87 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Prenetics Global is a strong investment it is important to analyze Prenetics Global's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Prenetics Global's future performance. For an informed investment choice regarding Prenetics Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prenetics Global. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Prenetics Stock refer to our How to Trade Prenetics Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Reinsurance space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prenetics Global. If investors know Prenetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prenetics Global listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.47) | Revenue Per Share 1.878 | Quarterly Revenue Growth 0.043 | Return On Assets (0.10) | Return On Equity (0.22) |
The market value of Prenetics Global is measured differently than its book value, which is the value of Prenetics that is recorded on the company's balance sheet. Investors also form their own opinion of Prenetics Global's value that differs from its market value or its book value, called intrinsic value, which is Prenetics Global's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prenetics Global's market value can be influenced by many factors that don't directly affect Prenetics Global's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prenetics Global's value and its price as these two are different measures arrived at by different means. Investors typically determine if Prenetics Global is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prenetics Global's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.